Compare American International Group Inc (AIG) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American International Group Inc vs Inovio Pharmaceuticals Inc — how do they compare? American International Group Inc trades at $80.36 (market cap $42.98B), while Inovio Pharmaceuticals Inc trades at $1.19 (market cap $99.55M). The key difference: American International Group Inc is far larger — about 431.7× Inovio Pharmaceuticals Inc's market cap, and American International Group Inc pays a 2.47% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AIG | INO | |
|---|---|---|
Market Cap | $42.98B | $99.55M |
Sector | Financials | Health |
52-Week High | $86.59 | $2.87 |
52-Week Low | $71.89 | $1.05 |
Enterprise Value | $50.68B | $70.56M |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIG trades at $81.06, up 2.1% today, showing strong momentum with three consecutive quarterly earnings beats. The stock is supported by bullish technical signals and a consensus price target of $88.13. Recent executive appointments and the acquisition of Everest Colombia signal strategic growth initiatives. Revenue stabilized around $26.8B in 2025 with net income margin improving to 11.88%.
Outlook remains positive with earnings growth and expansion in Latin America offering upside potential. Risks include catastrophe exposure and competitive pressures. Analysts are predominantly neutral with 58.5% Hold ratings, suggesting cautious optimism amid solid fundamentals.
INO trades at $1.21, down 2.02% today, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company shows minimal revenue of $65,340 (2025) with significant losses (-$84.95M net income), though recent earnings beats and FDA review of INO-3107 (PDUFA date October 30, 2026) provide catalysts. Analyst consensus is 53% buy, but multiple class action lawsuits pose legal risks.
Outlook hinges on FDA approval of INO-3107, which could drive upside, but high cash burn (-$21.54M net cash flow in 2025) and negative margins (-130,000% net income margin) underscore substantial operational risks. Investors face a binary event-driven opportunity with elevated volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
